Regional chemotherapy for liver-limited metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue 4, 2008, Pages 247-259

  Power, Derek G ^a   Healey Bird, Brian R ^a   Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

5 Fluoropyrimidines; Catheter blockage; Floxuridine; Hepatic arterial infusion; Irinotecan; Oxaliplatin

Indexed keywords

CETUXIMAB; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; MITOMYCIN C; NV 1020; OXALIPLATIN; PIRARUBICIN;

ABDOMINAL PAIN; ARTERY THROMBOSIS; ARTIFICIAL EMBOLISM; BILE ACID BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CATHETER ABLATION; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG DELIVERY SYSTEM; DRUG INFUSION; FIRST PASS EFFECT; HEALTH CARE COST; HEMATOMA; HEPATIC ARTERIAL INFUSION; HEPATIC ARTERY; HUMAN; INJECTION SITE INFECTION; LIVER METASTASIS; LIVER PERFUSION; LIVER RESECTION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; REVIEW; SIDE EFFECT; STOMATITIS; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 49149113233     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.n.032     Document Type: Review

References (122)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
3. Kemeny NE, Kemeny MM, Lawrence TS. Liver metastases. In: Abeloff MD, Armitage JO, Niederhuber JE et al, eds. Clinical Oncology, Third ed. Philadelphia: Elsevier Clinical Oncology 2004:1141-78.
4. Willett C, Tepper JE, Cohen A, et al. Local failure following curative resection of colonic adenocarcinoma. Int J Radiat Oncol Biol Phys 1984; 10:645-51.
5. Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004; 22:3766-75.
6. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24:3347-53.
7. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
8. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
10. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-18; discussion 318-21.
11. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77:1254-62.
12. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240:644-57; discussion 657-8.
13. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first line treatment for metastatic colorectal cancer. J Clin Oncol 2004; 22(14 suppl):248 (Abstract 3513).
14. Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-9.
15. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30:969-77.
16. Sullivan RD, Norcross JW, Watkins E Jr. Chemotherapy of Metastatic Liver Cancer by Prolonged Hepatic-Artery Infusion. N Engl J Med 1964; 270:321-7.
17. Koea JB, Kemeny N. Hepatic artery infusion chemotherapy for metastatic colorectal carcinoma. Semin Surg Oncol 2000; 19:125-34.
18. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10:176-82.
19. Ensminger WD. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29:119-25.
20. Balch CM, Urist MM. Intraarterial chemotherapy for colorectal liver metastases and hepatomas using a totally implantable drug infusion pump. Recent Results Cancer Res 1986; 100:234-47.
21. Cohen AM, Kaufman SD, Wood WC, et al. Regional hepatic chemotherapy using an implantable drug infusion pump. Am J Surg 1983; 145:529-33.
22. Kemeny N, Daly J, Oderman P, et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984; 2:595-600.
23. Niederhuber JE, Ensminger W, Gyves J, et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984; 53:1336-43.
24. Schwartz SI, Jones LS, McCune CS. Assessment of treatment of intrahepatic malignancies using chemotherapy via an implantable pump. Ann Surg 1985; 201:560-7.
25. Shepard KV, Levin B, Karl RC, et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985; 3:161-9.
26. Weiss GR, Garnick MB, Osteen RT, et al. Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol 1983; 1:337-44.
27. Cancer M-AGi. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996; 88:252-8.
28. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996; 78:1639-45.
29. Allen-Mersh TG, Earlam S, Fordy C, et al. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344:1255-60.
30. Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685-93.
31. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646-54.
32. Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459-65.
33. Martin JK, Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022-7.
34. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:1112-8.
35. Wagman LD, Kemeny MM, Leong L, et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8:1885-93.
36. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 2003; 361:368-73.
37. Lorenz M, Müller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18:243-54.
38. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395-403.
39. Kemeny N, Conti JA, Cohen A, et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12:2288-95.
40. Mocellin S, Pilati P, Lise M, et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 2007; 25:5649-54.
41. Kemeny N, Gonen M, Sullivan D, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19:2687-95.
42. Kemeny N, Eid A, Stockman J, et al. Hepatic arterial infusion of Floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 2005; 91:97-101.
43. Huitzil FD, Capanu M, Paty P, et al. Predictive factors for resection of unresectable metastases from colorectal cancer in patients treated with hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) plus IV oxaliplatin (Oxali) and irinotecan (CPT). Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-28; Orlando, FL. Abstract 361.
44. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888-96.
45. Shitara K, Munakata M, Kudo T, et al. Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer, [in Japanese]. Gan To Kagaku Ryoho 2006; 33:2033-7.
46. Gallagher DJ, Capanu M, Raggio G, et al. Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Ann Oncol 2007; 18:1995-9.
47. Kim JC, Kim HC, Lee KH, et al. Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer. J Gastroenterol Hepatol 2006; 21:1026-35.
48. Ensminger WD, Rosowsky A, Raso V. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2' -deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38:3784-92.
49. Boige V, Malka D, Elias D, et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008; 15:219-26.
50. Del Freo A, Fiorentini G, Sanguinetti F, et al. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer. In Vivo 2006; 20:743-6.
51. Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23:4881-7.
52. Bouchahda M, Tanaka K, Adam R, et al. Hepatic artery chronomodulated infusion of irinotecan, 5-fluorouracil and oxaliplatin against liver metastases in heavily pretreated patients with colorectal cancer. J Clin Oncol 2004; 22(14 suppl):300 (Abstract 3722).
53. Kern W, Beckert B, Lang N, et al. Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. Ann Oncol 2001; 12:599-603.
54. Fiorentini G, Rossi S, Dentico P, et al. Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a phase II clinical study. Tumori 2003; 89:382-4.
55. van Riel JM, van Groeningen CJ, Kedde MA, et al. Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002; 8:405-12.
56. Vogl TJ, Eichier K, Mack MG, et al. A phase I study of hepatic arterial infusion (HAI) of irinotecan in patients with inoperable liver metastases of colorectal cancer. J Clin Oncol 2004; 22(14 suppl):298 (Abstract 3714).
57. De Jong FA, Mathijssen RH, Verweij J. Limited potential of hepatic arterial infusion of irinotecan. J Chemother 2004; 16(suppl 5):48-50.
58. van Riel JM, van Groeningen CJ, de Greve J, et al. Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004; 15:59-63.
59. Mancuso A, Giuliani R, Accettura C, et al. Hepatic arterial continuous infusion (HACI) of oxaliplatin in patients with unresectable liver metastases from colorectal cancer. Anticancer Res 2003; 23:1917-22.
60. Cyjon A, Neuman-Levin M, Rakowsky E, et al. Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy. Br J Cancer 2001; 85:504-8.
61. Kohnoe S, Endo K, Yamamoto M, et al. Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. Surgery 2002; 131(1 suppl):S128-34.
62. Link KH, Pillasch J, Formentini A, et al. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 1999; 25:381-8.
63. Liu LX, Zhang WH, Jiang HC, et al. Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. World J Gastroenterol 2002; 8:663-7.
64. Tse AN, Raggio G, Morse M, et al. A phase I clinical and pharmacokinetic study of escalating doses of fixed rate and escalating infusion duration of gemcitabine given via an intrahepatic pump for patients with hepatic metastases. J Clin Oncol 2006; 24(18 suppl):626s (Abstract 14035).
65. Zelek L, Bugat R, Cherqui D, et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). Ann Oncol 2003; 14:1537-42.
66. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (d11520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62:6070-9.
67. Kemeny N, Brown K, Covey A, et al. Phase I, open-label, doseescalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 2006; 17:1214-24.
68. Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 2006; 24:4954-5.
69. Van Cutsem E, Nordlinger B, Adam R, et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42:2212-21.
70. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15:933-9.
71. Pozzo C, Basso M, Quirino M. Long-term follow-up of colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy with irinotecan and fluorouracil plus folinic acid (5-FU/FA) for unresectable liver metastases. J Clin Oncol 2006; 24(18 suppl):164s (Abstract 3576).
72. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007; 25(18 suppl):164s (Abstract 4000).
73. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25:5225-32.
74. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14:3188-94.
75. Taylor RA, White RR, Kemeny N, et al. Predictors of a true complete response in colorectal liver metastases that disappear radio-graphically following chemotherapy. J Clin Oncol 2007; 25(18 suppl):178s (Abstract 4058).
76. Nakajima Y, Nagao M, Ko S, et al. Clinical predictors of recurrence site after hepatectomy for metastatic colorectal cancer. Hepatogastroenterology 2001; 48:1680-4.
77. Topal B, Kaufman L, Aerts R, et al. Patterns of failure following curative resection of colorectal liver metastases. Eur J Surg Oncol 2003; 29:248-53.
78. Muratore A, Polastri R, Bouzari H, et al. Repeat hepatectomy for colorectal liver metastases: A worthwhile operation? J Surg Oncol 2001; 76:127-32.
79. O'Connell MJ, Adson MA, Schutt AJ, et al. Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver. Mayo Clin Proc 1985; 60:517-20.
80. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24:4976-82.
81. Parks R, Gonen M, Kemeny N, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204:753-61; discussion 61-3.
82. Mitry E, Fields A, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A meta-analysis of two randomized trials. J Clin Oncol 2006; 24(18 suppl):152s (Abstract 3524).
83. Kemeny MM, Goldberg D, Beatty JD, et al. Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986; 57:492-8.
84. Asahara T, Kikkawa M, Okajima M, et al. Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy. Hepatogastroenterology 1998; 45:805-11.
85. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy - an intergroup study. J Clin Oncol 2002; 20:1499-505.
86. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-48.
87. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Eng J Med 2005; 352:734-5.
88. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228:756-62.
89. Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immuno-chemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001; 48:1685-91.
90. Lygidakis NJ, Ziras N, Parissis J. Resection versus resection combined with adjuvant pre- and post-operative chemotherapy - immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 1995; 42:155-61.
91. O'Connell MJ, Bolton JS, Mahoney MR, et al. Final results of hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic (M-CRC) to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study. J Clin Oncol 2004; 22:252 (Abstract 3527).
92. Rudroff C, Altendorf-Hoffmann A, Stangl R, et al. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after RO resection of colorectal liver metastases. Langenbecks Arch Surg 1999; 384:243-9.
93. Tono T, Hasuike Y, Ohzato H, et al. Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: a randomized study. Cancer 2000; 88:1549-56.
94. Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 2003; 21:3303-9.
95. Gardini A, Ercolani G, Riccobon A, et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol 2004; 87:46-52.
96. Ota M, Shimada H, Masui H, et al. Adjuvant hepatic arterial infusion chemotherapy after curative resection for Dukes C colorectal cancer: a pilot study. Hepatogastroenterology 2004; 51:124-7.
97. Sadahiro S, Suzuki T, Ishikawa K, et al. Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial. Cancer 2004; 100:590-7.
98. Ito H, Are C, Gonen M, et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247:994-1002.
99. Kemeny N, Fata F Hepatic-arterial chemotherapy. Lancet Oncol 2001; 2:418-28.
100. Allen PJ, Nissan A, Picon AI, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 2005; 201:57-65.
101. Campbell KA, Burns RC, Sitzmann JV, et al. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol 1993; 11:822-6.
102. Curley SA, Chase JL, Roh MS, et al. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 1993; 114:928-35.
103. Heinrich S, Petrowsky H, Schwinnen I, et al. Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases. Surgery 2003; 133:40-8.
104. Scaife CL, Curley SA, Izzo F, et al. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol 2003; 10:348-54.
105. Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69:327-34.
106. Brown KT, Kemeny N, Berger MF, et al. Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: etiology, treatment implications, and complications after transhepatic biliary drainage. J Vasc Interv Radiol 1997; 8:229-34.
107. Davidson BS, Izzo F, Chase JL, et al. Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Am J Surg 1996; 172:244-7.
108. Tanaka K, Shimada H, Ueda M, et al. Perioperative complications after hepatectomy with or without intra-arterial chemotherapy for bilobar colorectal cancer liver metastases. Surgery 2006; 139:599-607.
109. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-72.
110. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surgery 2003; 7: 1034-44.
111. Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg 2006; 202:199-200.
112. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24:4983-90.
113. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243:1-7.
114. Venook AP, Stagg RJ, Lewis BJ, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8:1108-14.
115. Moertel CG. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1983; 1:727-40.
116. Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007; 246:559-65; discussion 65-7.
117. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004; 351:317-9.
118. Patt YZ. Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues. J Clin Oncol 1993; 11:815-9.
119. Durand-Zaleski I, Earlam S, Fordy C, et al. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer 1998; 83:882-8.
120. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion versus intravenous chemotherapy or symptom palliation in the treatment of nonresectable colorectal liver metastases. Meta-Analysis Group In Cancer. Crit Rev Oncol Hematol 1999; 32:125-31.
121. Durand-Zaleski I, Roche B, Buyse M, et al. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1997; 89:790-5.
122. Weeks JC, Romanus D, Herndon JE, et al. Cost-effectiveness of hepatic artery infusion for metastatic colorectal cancer (CALGB 9481). Value Health 2005; 8:A37.